KRAS and non-small cell lung carcinoma: The research which retrospectively analyzed 88 advanced NSCLC patients receiving immunotherapy disclosed that patients with KRAS mutation in immunotherapy had longer PFS and OS than the wild type (Dong et al. 2017).